非侵入性检查方法评价肝纤维化的研究进展(3)
[6]Orasan OH，Iancu M，Sava M，et al.Non-invasive assessment of liver fibrosis in chronic viral hepatitis[J].Eur J Clin Invest，2015，45(12)：1243-1251.
[7]Parsian H，Rahimipour A，Nouri M，et al.Assessment of liver fibrosis development in chronic hepatitis B patients by serum hyaluronic acid and laminin levels[J].Acta Clin Croat，2010，49(3)：257-265.
[8]Geramizadeh B，Janfeshan K，Saberfiroozi M.Serum hyaluronic acid as a noninvasive marker of hepatic fibrosis in chronic hepatitis B[J].Saudi J Gastroenterol，2008，14(4)：174-177.
, 百拇医药
[9]Chin JL，Pavlides M，Moolla A，et al.Non-invasive markers of liver Fibrosis：Adjuncts or alternatives to liver biopsy[J].Frontiers in Pharmacology，2016，7(159)：1-19.
[10]Thiele ND，Wirth JW，Steins D，et al.TIMP-1 is upregulated， but not essential in hepatic fibrogenesis and carcinogenesis in mice[J].Scientific Repo Rts，2017，7(1)：714-722.
[11]Lidbury JA，Hoffmann AR，Fry JK，et al.Evaluation of hyaluronic acid，procollagen type Ⅲ N-terminal peptide，and tissue inhibitor of matrix metalloproteinase-1 as serum markers of canine hepatic fibrosis[J].The Canadian Journal of eterinary Research，2016，80(4)：302-308.
, 百拇医药
[12]楊晴，刘东屏，李鲁平，等.慢性乙型肝炎肝纤维化非创伤性诊断模型的建立与评价[J].中华肝脏病杂志，2017，25(1)：15-20.
[13]Wu SD，Ni YJ，Liu LL，et al.Establishment and validation of a simple noninvasive model to predict significant liver fibrosis in patients with chronic hepatitis B[J].Hepatol Int，2012，6(1)：360-368.
[14]Bang CS，Kang HY，Choi GH，et al.The performance of serum biomarkers for predicting fibrosis in patients with chronic viral hepatitis[J].Korean J Gastroenterol，2017，69(5)：298-307.
, 百拇医药
[15]徐铭益，陆伦根.非创伤性诊断肝纤维化临床研究进展[J].传染病信息，2010，23(3)：129-132.
[16]Li Q，Lu C，Li W，et al.Impact of age on the diagnostic performances and cut-offs of APRI and FIB-4 for significant fibrosis and cirrhosis in chronic hepatitis B[J].Oncotarget，2017，8(28)：45768-45776.
[17]Zhu X，Wang LC，Chen EQ，et al.Prospective evaluation of FibroScan for the diagnosis of hepatic fibrosis ompared with liver biopsy AST platelet ratio index and FIB-4 in patients with chronic HBV infection[J].Dig Dis Sci，2011，56(9)：2742-2749.
, 百拇医药
[18]庄小芳，马燕，王晓忠，等.3种无创诊断技术对慢性乙型肝炎肝纤维化的评估价值比较[J].临床肝胆病杂志，2016，32(8)：1508-1512.
[19]Kim BK，Kim SU，Kim HS，et al.Prospective validation of Fibro Test in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B[J].PLoS One，2012，7(4)：e35825.
[20]Sebastiani G，Castera L，Halfon P，et al.The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers：an international study of 2411 cases[J].Aliment Pharmacol，2011，34(10)：1202-1216., 百拇医药(王艳欣 孟庆华 朱跃科)
[7]Parsian H，Rahimipour A，Nouri M，et al.Assessment of liver fibrosis development in chronic hepatitis B patients by serum hyaluronic acid and laminin levels[J].Acta Clin Croat，2010，49(3)：257-265.
[8]Geramizadeh B，Janfeshan K，Saberfiroozi M.Serum hyaluronic acid as a noninvasive marker of hepatic fibrosis in chronic hepatitis B[J].Saudi J Gastroenterol，2008，14(4)：174-177.
, 百拇医药
[9]Chin JL，Pavlides M，Moolla A，et al.Non-invasive markers of liver Fibrosis：Adjuncts or alternatives to liver biopsy[J].Frontiers in Pharmacology，2016，7(159)：1-19.
[10]Thiele ND，Wirth JW，Steins D，et al.TIMP-1 is upregulated， but not essential in hepatic fibrogenesis and carcinogenesis in mice[J].Scientific Repo Rts，2017，7(1)：714-722.
[11]Lidbury JA，Hoffmann AR，Fry JK，et al.Evaluation of hyaluronic acid，procollagen type Ⅲ N-terminal peptide，and tissue inhibitor of matrix metalloproteinase-1 as serum markers of canine hepatic fibrosis[J].The Canadian Journal of eterinary Research，2016，80(4)：302-308.
, 百拇医药
[12]楊晴，刘东屏，李鲁平，等.慢性乙型肝炎肝纤维化非创伤性诊断模型的建立与评价[J].中华肝脏病杂志，2017，25(1)：15-20.
[13]Wu SD，Ni YJ，Liu LL，et al.Establishment and validation of a simple noninvasive model to predict significant liver fibrosis in patients with chronic hepatitis B[J].Hepatol Int，2012，6(1)：360-368.
[14]Bang CS，Kang HY，Choi GH，et al.The performance of serum biomarkers for predicting fibrosis in patients with chronic viral hepatitis[J].Korean J Gastroenterol，2017，69(5)：298-307.
, 百拇医药
[15]徐铭益，陆伦根.非创伤性诊断肝纤维化临床研究进展[J].传染病信息，2010，23(3)：129-132.
[16]Li Q，Lu C，Li W，et al.Impact of age on the diagnostic performances and cut-offs of APRI and FIB-4 for significant fibrosis and cirrhosis in chronic hepatitis B[J].Oncotarget，2017，8(28)：45768-45776.
[17]Zhu X，Wang LC，Chen EQ，et al.Prospective evaluation of FibroScan for the diagnosis of hepatic fibrosis ompared with liver biopsy AST platelet ratio index and FIB-4 in patients with chronic HBV infection[J].Dig Dis Sci，2011，56(9)：2742-2749.
, 百拇医药
[18]庄小芳，马燕，王晓忠，等.3种无创诊断技术对慢性乙型肝炎肝纤维化的评估价值比较[J].临床肝胆病杂志，2016，32(8)：1508-1512.
[19]Kim BK，Kim SU，Kim HS，et al.Prospective validation of Fibro Test in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B[J].PLoS One，2012，7(4)：e35825.
[20]Sebastiani G，Castera L，Halfon P，et al.The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers：an international study of 2411 cases[J].Aliment Pharmacol，2011，34(10)：1202-1216., 百拇医药(王艳欣 孟庆华 朱跃科)